Inferra AI / Company / PRAX
Praxis Precision Medicines, Inc.
PRAX · Health Care
Last earnings Aug 6, 2026
AI analysis
Q2 2025 · reported Aug 4, 2025
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
The event-summary record for this company carries no extracted figures, so the brief and charts cannot be drawn yet. The summary below and the held documents are the record for this event.
Guidance · company-stated
No guidance located in the held release
Capital allocation
The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2026 of $ 1.4 billion will be sufficient to fund its operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these condensed 7 consolidated financial statements.
government agencies 277,132 ( 656 ) 276,476 Corporate debt securities 293,902 ( 678 ) 293,224 Asset backed securities 68,267 ( 59 ) 68,208 Commercial paper 14,466 ( 25 ) 14,441 Other debt securities 247,985 ( 1,254 ) 246,731 Total cash equivalents and marketable securities $ 980,995 $ $ ( 2,672 ) $ 978,323 As of December 31, 2025 Gross Unrealized Estimated Cost Gains Losses Fair Value Cash equivalents: Money market funds $ 195,296 $ $ $ 195,296 Debt securities issued by U.
Event summary
Earlier today we reported the positive results from the RADIANT study, where vormatrigine has shown an impressive 56.3% reduction in seizures in 8 weeks in a heavily pre-treated population
Based on: Earnings release + Q2 2025 deck + parent 8-K + 10-Q — transcript not held
Guidance & outlook
No guidance located in the held release
Capital allocation
The Company expects that its cash, cash equivalents and marketable securities as of June 30, 2026 of $ 1.4 billion will be sufficient to fund its operating expenditures and capital expenditure requirements necessary to advance its research efforts and clinical trials for at least one year from the date of issuance of these condensed 7 consolidated financial statements.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
government agencies 277,132 ( 656 ) 276,476 Corporate debt securities 293,902 ( 678 ) 293,224 Asset backed securities 68,267 ( 59 ) 68,208 Commercial paper 14,466 ( 25 ) 14,441 Other debt securities 247,985 ( 1,254 ) 246,731 Total cash equivalents and marketable securities $ 980,995 $ $ ( 2,672 ) $ 978,323 As of December 31, 2025 Gross Unrealized Estimated Cost Gains Losses Fair Value Cash equivalents: Money market funds $ 195,296 $ $ $ 195,296 Debt securities issued by U.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
government agencies 7,003 ( 1 ) 7,002 Available-for-sale securities: Corporate debt securities 198,036 282 198,318 Debt securities issued by U.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
government agencies 183,739 258 183,997 Asset backed securities 61,282 70 61,352 Commercial paper 7,714 4 7,718 Other debt securities 117,424 ( 50 ) 117,374 Total cash equivalents and marketable securities $ 770,494 $ 614 $ ( 51 ) $ 771,057 As of June 30, 2026, the Company had 180 securities with a total fair market value of $ 793.8 million in an unrealized loss position.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company believes that any unrealized losses associated with the decline in value of its securities is temporary and primarily related to the change in market interest rates since purchase, and believes that it is more likely than not that it will be able to hold its debt securities to maturity.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
The Company anticipates a full recovery of the amortized cost basis of its debt securities at maturity and an allowance was not recognized.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Strategy & priorities
Praxis remains on track to nominate a development candidate for each of its early stage ASO therapeutic initiatives in 2025 o PRAX-080 Focused on targeting PCDH19 mosaic expression disorder, nominated by end of year.
SEC original ↗Praxis Precision Medicines, Inc. — Earnings release (8-K exhibit)EX-99Aug 4, 2025
The Company's inability to raise capital as and when needed could have a negative impact on its financial condition and ability to pursue its business strategies.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Risks & headwinds
New risks and uncertainties may emerge from time to time, and it is not possible to predict all risks and uncertainties.
SEC original ↗Praxis Precision Medicines, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025
For further information regarding the risks, uncertainties and other factors that may cause differences between our expectations and actual results, you should review the Risk Factors section of our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission ( SEC ) and our other filings with the SEC.
SEC original ↗Praxis Precision Medicines, Inc. — Presentation / slide deck (8-K exhibit)EX-99Aug 4, 2025
Although we believe that the expectations reflected in these forward-looking statements are reasonable, these statements relate to future events or our future operational or financial performance, and involve known and unknown risks, uncertainties and other factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by these forward-looking statements.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
You should not place undue reliance on forward-looking statements because they involve known and unknown risks, uncertainties, and other factors, which are, in some cases, beyond our control and which could materially affect results.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
If one or more of these risks or uncertainties occur, or if our underlying assumptions prove to be incorrect, actual events or results may vary significantly from those implied or projected by the forward-looking statements.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Information that is based on estimates, forecasts, projections, market research or similar methodologies is inherently subject to uncertainties and actual events or circumstances may differ materially from events and circumstances that are assumed in this information.
SEC original ↗Praxis Precision Medicines, Inc. — 10-Q Quarterly report10-QAug 6, 2026
Earnings deck slides
0 decks with slide viewPraxis Precision Medicines, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Praxis Precision Medicines, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Praxis Precision Medicines, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Praxis Precision Medicines, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Praxis Precision Medicines, Inc. — Presentation / slide deck (8-K exhibit) — Slide view unavailable — this deck was filed as a web document, whose text has no page boundaries.
Competitors
Competitors & peers
Same GICS sector — classification peers, not declared competitors
Filings
32 documentsEarnings releases
4 documentsPresentations
5 documents
Transcripts
0 documentsNo transcripts for Praxis Precision Medicines, Inc. are held in this edition of the library.
See also the earnings calendar for every tracked company’s next earnings date.